HRP20140631T1 - Polimerni sustav za dostavu neviskozne otopine bez konzervansa zasnovane na prostaglandinu - Google Patents
Polimerni sustav za dostavu neviskozne otopine bez konzervansa zasnovane na prostaglandinu Download PDFInfo
- Publication number
- HRP20140631T1 HRP20140631T1 HRP20140631AT HRP20140631T HRP20140631T1 HR P20140631 T1 HRP20140631 T1 HR P20140631T1 HR P20140631A T HRP20140631A T HR P20140631AT HR P20140631 T HRP20140631 T HR P20140631T HR P20140631 T1 HRP20140631 T1 HR P20140631T1
- Authority
- HR
- Croatia
- Prior art keywords
- solution according
- solution
- prostaglandin
- agent
- ethyl
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims 4
- 239000000243 solution Substances 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229960001631 carbomer Drugs 0.000 claims 3
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 2
- 239000003349 gelling agent Substances 0.000 claims 2
- 229960001160 latanoprost Drugs 0.000 claims 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 2
- 229920001684 low density polyethylene Polymers 0.000 claims 2
- 239000004702 low-density polyethylene Substances 0.000 claims 2
- 229940054534 ophthalmic solution Drugs 0.000 claims 2
- 239000002997 ophthalmic solution Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- HLETUMXUCSCVPL-GWSKAPOCSA-N (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]cyclopentyl]-n-ethylhept-5-enamide Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)NCC HLETUMXUCSCVPL-GWSKAPOCSA-N 0.000 claims 1
- RAGQWYIPCPFTJC-KDACTHKWSA-N 17-phenyl-trinor-PGF2alpha amide Chemical compound NC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 RAGQWYIPCPFTJC-KDACTHKWSA-N 0.000 claims 1
- XCVCLIRZZCGEMU-PSTSCRTLSA-N 7-[(2r)-3,5-dihydroxy-2-(3-hydroxyoct-1-enyl)cyclopentyl]-n-(2-hydroxyethyl)hept-5-enamide Chemical compound CCCCCC(O)C=C[C@H]1C(O)CC(O)C1CC=CCCCC(=O)NCCO XCVCLIRZZCGEMU-PSTSCRTLSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 1
- KNXVTDOCIZLXFW-SQACBOECSA-N Latanoprost ethyl amide Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 KNXVTDOCIZLXFW-SQACBOECSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- FPABVZYYTCHNMK-YNRDDPJXSA-N PGF2alpha isopropyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C FPABVZYYTCHNMK-YNRDDPJXSA-N 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000000030 antiglaucoma agent Substances 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 229940072106 hydroxystearate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960004458 tafluprost Drugs 0.000 claims 1
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Oftalmička otopina koja uključuje:
- najmanje jedan prostaglandin;
- otapajući agens;
- gelirajući agens tipa karbomera;
- agens za inhibiciju polimerizacije karbomera;
- agens za ko-geliranje/ko-otapanje,
Gdje:
- otopina ima Brookfield viskoznost pri 25°C u rasponu od 8 mPa.s do 20 mPa.s; otopina ne sadrži antimikrobske konzervanse.
2. Otopina prema zahtjevu 1, naznačena time da ima Brookfield viskoznost u rasponu od 10 mPas.s do 14 mPa.s.
3. Otopina prema zahtjevu 1 ili 2, naznačena time da su antimikrobski konzervansi tipa kvarternog amonijaka, još poželjnije tip benzalkonij-klorida (BAK).
4. Otopina prema zahtjevu 1 ili 2, naznačena time da je koncentracija gelirajućeg agensa tipa karbomera u rasponu od 0,05% do 0,15% (w/v).
5. Otopina prema bilo kojem od zahtjeva 1 do 4, naznačena time da se prostaglandin bira iz skupine koja uključuje 17-fenil-13,14 dihidro trinor Prostaglandin F2α izopropil ester (latanoprost), 20-etil Prostaglandin F2a, (+)-Fluprostenol izopropil ester (travoprost), 17-fenil trinor Prostaglandin F2α amid, 7-fenil-13,14 dihidro trinor Prostaglandin F2α etil amid (bimatoprost), tafluprost Prostaglandin F2α etanolamid, bimatoprost (slobodna kiselina)-d4, bimatoprost-d4, latanoprost etil amid, 13,14 dihidro-15-keto-20-etil Prostaglandin F2α (unoproston), 13,14 dihidro-15-keto-20-etil Prostaglandin F2α izopropil ester (unoproston izopropil ester), poželjno latanoprost.
6. Otopina prema bilo kojem od zahtjeva 1 do 5, naznačena time da je koncentracija prostaglandina u otopini između 0,002% i 0,15% (w/v).
7. Otopina prema bilo kojem od zahtjeva 1 do 6, naznačena time da je inhibirajući agens za polimerizaciju karbomera izvor iona natrija, poželjno EDTA natrija, natrij-acetata ili natrij- klorida.
8. Otopina prema bilo kojem od zahtjeva 1 do 7, naznačena time da je otapajući agens hidroksistearat makroglicerola.
9. Otopina prema bilo kojem od zahtjeva 1 do 8, naznačena time da je ko-gelirajući/ ko-otapajući agens polimer izabran iz skupine koja uključuje polietilenglikol (PEG), polivinilski alkohol (PVA) ili polivinilpirolidon (PVP).
10. Otopina prema bilo kojem od zahtjeva 1 do 9, naznačena time da je otopina stabilna najmanje 18 mjeseci pri temperaturi okoline (25°C ili 30°C).
11. Otopina prema bilo kojem od zahtjeva 1 do 10, naznačena time da je otopina kompatibilna sa bočicama za jednokratnu ili multidoznu upotrebu napravljenim od LDPE bez aditiva.
12. Otopina prema bilo kojem od zahtjeva 1 do 11, naznačena time da također sadrži antiglaukomatski agens izabran iz skupine koja uključuje beta blokatore, inhibitore ugljične anhidraze i alfa-adrenergične agoniste.
13. Otopina prema bilo kojem od zahtjeva 1 do 12, naznačena time da također sadrži aditiv izabran iz skupine koja uključuje izotonične agense, antioksidanse i puferske sustave.
14. Otopina prema bilo kojem od zahtjeva 1 do 13 za upotrebu u tretiranju glaukome i/ili smanjenje intraokularnog pritiska.
15. Otopina prema zahtjevu 14 uključujući da se topički administrira jedna kap spomenute otopine po danu u svako oko ljudi ili životinja.
16. Bočica za jednokratnu ili multidoznu upotrebu napravljena od LDPE bez aditiva koja sadrži oftalmičku otopinu pokrivenu bilo kojim od zahtjeva 1 do 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35969910P | 2010-06-29 | 2010-06-29 | |
| FR1055236A FR2961694B1 (fr) | 2010-06-29 | 2010-06-29 | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| PCT/EP2011/060848 WO2012001009A1 (fr) | 2010-06-29 | 2011-06-28 | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140631T1 true HRP20140631T1 (hr) | 2014-09-26 |
Family
ID=43064334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140631AT HRP20140631T1 (hr) | 2010-06-29 | 2014-07-02 | Polimerni sustav za dostavu neviskozne otopine bez konzervansa zasnovane na prostaglandinu |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20110319487A1 (hr) |
| EP (1) | EP2588078B1 (hr) |
| JP (2) | JP5657789B2 (hr) |
| KR (1) | KR101809713B1 (hr) |
| CN (2) | CN104274396B (hr) |
| AU (1) | AU2011273549B2 (hr) |
| BR (1) | BR112012033435B1 (hr) |
| CA (1) | CA2802816C (hr) |
| CL (1) | CL2012003684A1 (hr) |
| CO (1) | CO6660508A2 (hr) |
| DK (1) | DK2588078T3 (hr) |
| EA (1) | EA025026B1 (hr) |
| ES (1) | ES2486793T3 (hr) |
| FR (1) | FR2961694B1 (hr) |
| HK (2) | HK1178446A1 (hr) |
| HR (1) | HRP20140631T1 (hr) |
| MA (1) | MA34324B1 (hr) |
| MX (1) | MX2012014503A (hr) |
| PL (1) | PL2588078T3 (hr) |
| PT (1) | PT2588078E (hr) |
| RS (1) | RS53417B (hr) |
| SG (1) | SG186361A1 (hr) |
| SI (1) | SI2588078T1 (hr) |
| SM (1) | SMT201400098B (hr) |
| TN (1) | TN2012000588A1 (hr) |
| UA (1) | UA107718C2 (hr) |
| WO (1) | WO2012001009A1 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US9278132B2 (en) * | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
| AU2014225305B2 (en) * | 2013-03-08 | 2019-01-31 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
| US10113033B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
| CN104288092A (zh) * | 2013-07-16 | 2015-01-21 | 广东东阳光药业有限公司 | 拉坦前列素滴眼剂 |
| US9115109B2 (en) * | 2013-08-15 | 2015-08-25 | Chirogate International Inc. | Processes and intermediates for the preparations of isomer free prostaglandins |
| EP3057575B1 (en) * | 2013-10-15 | 2021-09-08 | Pharmathen S.A. | Preservative free pharmaceutical compositions for ophthalmic administration |
| GR1008330B (el) * | 2013-10-17 | 2014-10-20 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση εχoν βελτιωμενες φυσικες ιδιοτητες και ογκο σταγονας |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| CN105012231A (zh) * | 2014-04-30 | 2015-11-04 | 四川科伦药物研究院有限公司 | 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法 |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| ES2747302T3 (es) * | 2015-06-09 | 2020-03-10 | Medproject Pharma Entw Und Vertriebsgesellschaft Mbh | Gel oftálmico de bimatoprost aplicable en gotas |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| WO2018033854A1 (en) * | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
| WO2018045091A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
| IT201600103956A1 (it) * | 2016-10-17 | 2018-04-17 | Omikron Italia S R L | Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma |
| KR101770324B1 (ko) * | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
| CA3054084A1 (en) | 2017-03-14 | 2018-09-20 | Polyactiva Pty Ltd | Biodegradable drug-polymer conjugate |
| US11696955B2 (en) | 2017-03-14 | 2023-07-11 | Polyactiva Pty Ltd | Drug-polymer conjugate |
| US11207417B2 (en) | 2017-03-14 | 2021-12-28 | Polyactiva Pty Ltd | Drug-polymer conjugate |
| CN110785162B (zh) | 2017-06-22 | 2023-08-01 | Ys生命科学株式会社 | 用于治疗青光眼的滴眼液组合物 |
| LT3593788T (lt) * | 2018-07-12 | 2021-04-12 | Nicox S.A. | Oftalminės kompozicijos, kurių sudėtyje yra azoto oksidą atpalaiduojantis prostamidas |
| WO2020028055A1 (en) * | 2018-07-31 | 2020-02-06 | ADLER, Benjamin, Aaron | Ophthalmic formulations and uses thereof |
| US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CN110711175A (zh) * | 2019-11-12 | 2020-01-21 | 南京华盖制药有限公司 | 一种他氟前列素滴眼剂及其制备方法 |
| US20230263727A1 (en) * | 2022-01-14 | 2023-08-24 | Somerset Therapeutics, Llc | Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10021A (en) * | 1853-09-13 | Screw-eastemtito- for boots and shoes | ||
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6646001B2 (en) * | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| DE69918122T2 (de) * | 1998-04-02 | 2005-06-16 | Novartis Ag | Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans |
| US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| ES2667945T3 (es) * | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| BRPI0818459A2 (pt) * | 2007-10-16 | 2015-04-14 | Sun Pharma Advanced Res Co Ltd | Composição farmacêutica adequada para uso oftálmico. |
| EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
-
2010
- 2010-06-29 FR FR1055236A patent/FR2961694B1/fr active Active
-
2011
- 2011-06-28 CA CA2802816A patent/CA2802816C/fr active Active
- 2011-06-28 AU AU2011273549A patent/AU2011273549B2/en active Active
- 2011-06-28 US US13/170,716 patent/US20110319487A1/en not_active Abandoned
- 2011-06-28 MA MA35472A patent/MA34324B1/fr unknown
- 2011-06-28 SG SG2012092284A patent/SG186361A1/en unknown
- 2011-06-28 EP EP11727707.9A patent/EP2588078B1/fr active Active
- 2011-06-28 CN CN201410538280.1A patent/CN104274396B/zh active Active
- 2011-06-28 PT PT117277079T patent/PT2588078E/pt unknown
- 2011-06-28 BR BR112012033435-2A patent/BR112012033435B1/pt active IP Right Grant
- 2011-06-28 SI SI201130234T patent/SI2588078T1/sl unknown
- 2011-06-28 EA EA201291307A patent/EA025026B1/ru not_active IP Right Cessation
- 2011-06-28 PL PL11727707T patent/PL2588078T3/pl unknown
- 2011-06-28 WO PCT/EP2011/060848 patent/WO2012001009A1/fr active Application Filing
- 2011-06-28 ES ES11727707.9T patent/ES2486793T3/es active Active
- 2011-06-28 CN CN201180032001.9A patent/CN102958509B/zh active Active
- 2011-06-28 MX MX2012014503A patent/MX2012014503A/es active IP Right Grant
- 2011-06-28 DK DK11727707.9T patent/DK2588078T3/da active
- 2011-06-28 RS RS20140353A patent/RS53417B/en unknown
- 2011-06-28 JP JP2013517254A patent/JP5657789B2/ja active Active
- 2011-06-28 KR KR1020127033996A patent/KR101809713B1/ko active IP Right Grant
- 2011-06-28 UA UAA201301063A patent/UA107718C2/ru unknown
-
2012
- 2012-08-27 US US13/595,165 patent/US8637054B2/en active Active
- 2012-12-12 TN TNP2012000588A patent/TN2012000588A1/fr unknown
- 2012-12-26 CL CL2012003684A patent/CL2012003684A1/es unknown
- 2012-12-27 CO CO12234226A patent/CO6660508A2/es not_active Application Discontinuation
-
2013
- 2013-05-06 HK HK13105429.5A patent/HK1178446A1/xx unknown
-
2014
- 2014-07-02 HR HRP20140631AT patent/HRP20140631T1/hr unknown
- 2014-07-23 SM SM201400098T patent/SMT201400098B/xx unknown
- 2014-09-19 JP JP2014191849A patent/JP5877885B2/ja active Active
-
2015
- 2015-02-27 HK HK15102052.4A patent/HK1201464A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140631T1 (hr) | Polimerni sustav za dostavu neviskozne otopine bez konzervansa zasnovane na prostaglandinu | |
| JP2021035984A (ja) | ポビドンヨード、眼科用組成物のための新規代替保存剤 | |
| US8129431B2 (en) | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | |
| CN101400354B (zh) | 水性组合物 | |
| US20110118348A1 (en) | Methods of stabilizing latanoprost in an aqueous solution | |
| RU2016139698A (ru) | Фармацевтическая комбинированная композиция для местного и наружного применения на основе диоксидина | |
| RU2011143860A (ru) | Безфосфатный лекарственный препарат для лечения глаукомы | |
| KR20050057251A (ko) | 라타노프로스트를 유효 성분으로 하는 투명한 점안액 | |
| JP5593345B2 (ja) | イソプロピルウノプロストンの分解抑制方法 | |
| AU2013344497B2 (en) | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | |
| ES2431640T3 (es) | Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad | |
| JP2005263792A (ja) | 澄明なラタノプロスト点眼液 | |
| ES2883956T3 (es) | Composición oftálmica que comprende ácido lipoico y ácido hialurónico | |
| JP5253775B2 (ja) | ラタノプロスト点眼剤 | |
| AR090083A1 (es) | Proceso para preparar una solucion no viscosa a base de prostaglandina | |
| JP2015024990A (ja) | 水性医薬組成物 | |
| US10722498B2 (en) | Acetazolamide ophthalmic solution | |
| JP2017137345A (ja) | ドルゾラミド、高分子およびホウ酸を含有する医薬組成物 | |
| JP2015086222A (ja) | 安定化された２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| JP2007176932A (ja) | 粘膜適用液剤 | |
| JP2010132572A (ja) | 眼科用剤 | |
| GB2465746A (en) | Pharmaceutical composition for topical application | |
| WO2005079809A1 (ja) | 澄明なラタノプロスト点眼液 | |
| ITRM20120361A1 (it) | Soluzioni oftalmiche per uso topico contenenti acido ialuronico crosslinkato |